Concepedia

Jesse Hall

JH

Statistics

Publications

16

Citations

740

H-Index

13

Active since

2000

Affiliations

AstraZeneca (United States)(Current)

The University of Texas Southwestern Medical Center

Amgen (United States)

Inserm

Colorado Center for Bone Research

Jesse Hall is an author at AstraZeneca (United States) specializing in medicine, treatment of asymptomatic hyperuricemia, and pharmacology.

ORCID

Publications per year

2000–2018

16

Publications

16

A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density

Eric Orwoll, Christence Stubbe Teglbjærg, Bente Langdahl et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 231 citations · Full text

, , +16

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

Chris Recknor, E. J. Czerwiński, Henry G. Bone et al. · Obstetrics and Gynecology · 2013 · 130 citations · Full text

, , +16

Renal Replacement Therapy for Acute Renal Failure

Patrick Murray, Jesse Hall · American Journal of Respiratory and Critical Care Medicine · 2000 · 78 citations

, , +6

Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

David Fitzpatrick, Kent Roberson, Kiyoshi Niwa et al. · Modern Rheumatology · 2018 · 50 citations · Full text

, , +12

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects

Zancong Shen, Michael Gillen, Jeffrey N. Miner et al. · Drug Design Development and Therapy · 2017 · 40 citations · Full text

, , +14

1–5 of 16